Vnitr Lek 2025, 71(2):86-92 | DOI: 10.36290/vnl.2025.016
What do the new ESC 2024 guidelines for the treatment of hypertension offer and how do they differ from ESH 2023?
- 1 Klinika tělovýchovného lékařství a kardiovaskulární rehabilitace, Fakultní nemocnice Olomouc
- 2 Lékařská fakulta, Univerzita Palackého, Olomouc
- 3 Interní a kardiologická klinika, Fakultní nemocnice Ostrava
- 4 Lékařská fakulta, Ostravská univerzita, Ostrava
Although the prevalence of arterial hypertension is increasing worldwide, the percentage of patients with controlled hypertension is also increasing. In diagnosing and treating arterial hypertension, doctors can rely on the European Society of Cardiology (ESC) 2024 and European Society of Hypertension (ESH) 2023 guidelines. Both sets of guidelines emphasize existing and add new recommendations. Values in the range of 120-139/70-89 mm Hg are now considered elevated blood pressure by ESC. In the diagnosis of hypertension, there is consensus on the emphasis on out-of-hospital blood pressure measurement. Initiation of pharmacotherapy is indicated in all patients with hypertension along with non-pharmacological measures. In most patients with hypertension, except for the old and frail, pharmacotherapy is initiated with a fixed two-combination at lower doses, the second step being a three-combination at lower doses. In patients with elevated blood pressure and high cardiovascular risk, pharmacotherapy is also newly recommended. Target values for systolic blood pressure are in the range 120-129 mm Hg, diastolic < 80 mm Hg. Furthermore, both sets of recommendations offer answers to many specific situations related to specific patient groups such as younger patients, older patients, pregnant women, patients with renal insufficiency, etc.
Keywords: arterial hypertension, guidelines, European Society of Hypertension, European Society of Cardiology.
Accepted: March 18, 2025; Published: March 27, 2025 Show citation
References
- WHO Cardiovascular diseases factsheet. [Internet] [cit 2024-12-07]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
- Zemřelí 2018. [Internet] [cit 2024-12-07]. Available from: https://www.uzis.cz/res/f/008309/demozem2018.pdf.
- Zhou B, Bentham J, Di Cesare M, et al. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. The Lancet. 2017;389(10064):37-55. doi:10.1016/S0140-6736(16)31919-5.
Go to original source...
Go to PubMed...
- Cífková R, Bruthans J, Wohlfahrt P, et al. Prevalence hlavních rizikových faktorů kardiovaskulárních onemocnění v české populaci v letech 2015-2018. Studie Czech post-MONICA. Cor Vasa. 2020;62(1):6-16. doi:10.33678/cor.2020.010.
Go to original source...
- McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018. doi:10.1093/eurheartj/ehae178.
Go to original source...
Go to PubMed...
- Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874-2071. doi:10.1097/HJH.0000000000003480.
Go to original source...
Go to PubMed...
- Virdis A, Muiesan ML, Grassi G. Juxtaposing Hypertension Guidelines: Are They Different? A Pragmatic Look to ESC and ESH Guidelines on (Arterial) Hypertension. High Blood Press Cardiovasc Prev Off J Ital Soc Hypertens. Published online November 19, 2024. doi:10.1007/s40292-024-00693-7.
Go to original source...
Go to PubMed...
- Malik R, Georgakis MK, Vujkovic M, et al. Relationship Between Blood Pressure and Incident Cardiovascular Disease: Linear and Nonlinear Mendelian Randomization Analyses. Hypertens Dallas Tex 1979. 2021;77(6):2004-2013. doi:10.1161/HYPERTENSIONAHA.120.16534
Go to original source...
Go to PubMed...
- Forouzanfar MH, Liu P, Roth GA, et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;317(2):165-182. doi:10.1001/jama.2016.19043.
Go to original source...
Go to PubMed...
- Ji H, Niiranen TJ, Rader F, et al. Sex Differences in Blood Pressure Associations With Cardiovascular Outcomes. Circulation. 2021;143(7):761-763. doi:10.1161/CIRCULATIONAHA.120.049360.
Go to original source...
Go to PubMed...
- SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439-2454. doi:10.1093/eurheartj/ehab309.
Go to original source...
Go to PubMed...
- SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J. 2023;44(28):2544-2556. doi:10.1093/eurheartj/ehad260.
Go to original source...
Go to PubMed...
- Andreasova T, Malek F, Jiraskova Zakostelska Z, Neuzil P, Vranova J. Association of biomarkers of cardiac remodeling, myocardial fibrosis and inflammation with parameters of heart function and structure in patients with arterial hypertension. Biomed Pap Med Fac Univ Palacky Olomouc Czechoslov. Published online November 6, 2024. doi:10.5507/bp.2024.036.
Go to original source...
Go to PubMed...
- Ballut OM, Alzahrani AA, Alzahrani RA, et al. The Impact of Non-pharmacological Interventions on Blood Pressure Control in Patients With Hypertension: A Systematic Review. Cureus. 15(11):e48444. doi:10.7759/cureus.48444.
Go to original source...
Go to PubMed...
- Filippou CD, Tsioufis CP, Thomopoulos CG, et al. Dietary Approaches to Stop Hypertension (DASH) Diet and Blood Pressure Reduction in Adults with and without Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Adv Nutr Bethesda Md. 2020;11(5):1150-1160. doi:10.1093/advances/nmaa041.
Go to original source...
Go to PubMed...
- Mancia G, Brunström M, Burnier M, et al. Rationale for the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines. Hypertens Dallas Tex 1979. 2024;81(5):1021-1030. doi:10.1161/HYPERTENSIONAHA.124.22821.
Go to original source...
Go to PubMed...
- Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res. 2011;34(1):87-90. doi:10.1038/hr.2010.183.
Go to original source...
Go to PubMed...
- O'Caoimh R, Sezgin D, O'Donovan MR, et al. Prevalence of frailty in 62 countries across the world: a systematic review and meta-analysis of population-level studies. Age Ageing. 2021;50(1):96-104. doi:10.1093/ageing/afaa219.
Go to original source...
Go to PubMed...
- Brown JM, Siddiqui M, Calhoun DA, et al. The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study. Ann Intern Med. 2020;173(1):10-20. doi:10.7326/M20-0065.
Go to original source...
Go to PubMed...